

# Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Information for the public  
Published: 20 March 2019

[www.nice.org.uk](http://www.nice.org.uk)

Pertuzumab (Perjeta), with trastuzumab and chemotherapy, is available on the NHS. It is a possible option, after surgery, for treating human epidermal growth factor receptor 2 (HER2)-positive early breast cancer that had spread to nearby lymph nodes.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The NHS website may be a good place to find out more about breast cancer in [women](#) and [men](#).

These organisations can give you advice and support:

- [Breast Cancer Care](#), 0808 800 6000
- [Breast Cancer Now](#), 0333 20 70 300
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3324-2